Food allergy immunotherapy: milestones on the treatment path

For children, it is a carefully staged management pathway in which the immune system is repeatedly exposed to a measured amount of the trigger food, beginning with a medically supervised escalation dose and progressing toward regular maintenance.

That distinction matters. Families often ask when a child will be “cured,” while the clinically useful questions are more specific: How much allergen can the child tolerate? Has the reaction threshold increased? Can accidental exposure be met with greater protection? Is daily treatment improving quality of life enough to justify its burden and risk?

When we discuss food allergy immunotherapy milestones in children, we are therefore tracking several outcomes at once: the safety of dose increases, the development of desensitization, the child’s ability to remain on maintenance, and the practical effect on everyday family life.

The clinical architecture of desensitization: from escalation to maintenance

The first milestone is not the daily maintenance dose. It is confirming that oral immunotherapy is appropriate for the child and that the family can follow the protocol safely.

A pediatric allergist usually brings together the child’s clinical presentation, allergy testing, previous reaction history, other allergic disease, asthma control, medication use, and the family’s ability to manage an emergency reaction. A positive test alone does not describe the full risk profile, and the size of an IgE result does not function as a simple forecast of how much food a child will tolerate. We need the entire clinical picture before selecting a treatment pathway.

For peanut oral immunotherapy, the treatment architecture has been standardized more clearly than for many other allergens. In January 2020, the U.S. Food and Drug Administration approved Palforzia, a peanut allergen powder designed for pediatric oral immunotherapy. Its standard daily target maintenance dose is 300 mg of peanut protein, roughly equivalent to one peanut kernel.

The milestones generally follow this sequence:

1. Clinical assessment and preparation.

We review the diagnosis, assess coexisting asthma or eczema, discuss the emergency plan, and make sure caregivers understand how doses will be given and recorded. This stage also includes a realistic conversation about adherence: OIT is a daily treatment, not an occasional exposure exercise.

2. Initial dose escalation.

Several gradually increasing doses may be administered during a supervised visit. The purpose is to identify a tolerated starting dose and to observe the child in a setting where trained staff and emergency treatment are available.

3. Up-dosing.

The child takes the prescribed dose at home for a period of time, followed by a planned increase under the treating team’s protocol. The dose may be adjusted or held when symptoms occur, during an intercurrent illness, or when other clinical factors make escalation less appropriate.

4. Maintenance.

Once the target dose is reached, the child continues taking it regularly. This phase is not an endpoint in the sense of a completed cure; it is the ongoing exposure that helps preserve desensitization.

5. Assessment of protection.

In selected circumstances, the team may evaluate the child through a medically supervised oral food challenge or another structured assessment. The result describes the child’s response under that specific protocol and should not be interpreted as permission to change treatment independently.

The exact schedule varies according to the allergen, product, age of the child, local practice, and trial or clinical protocol. There is no single universal up-dosing pathway for every food. Peanut OIT has the most established standardized framework, while approaches involving sesame, tree nuts, egg, or other allergens may differ substantially between specialist centers.

The meaningful endpoint is not simply reaching a dose; it is achieving a safer, sustainable routine without losing sight of the child’s overall quality of life.

What happens around each dose

Families often receive more value from understanding the conditions around dosing than from memorizing the dose numbers alone. Oral immunotherapy is usually given with a consistent routine, and the clinical team may advise that the child should not take a dose when acutely unwell or when symptoms could make an allergic reaction harder to recognize.

Exercise, bathing, fever, gastrointestinal illness, and poorly controlled asthma can become relevant co-factors in individual management plans. The instructions are not interchangeable between protocols, so we should avoid borrowing a rule from another child’s treatment. A dose that is appropriate for one patient may not be appropriate for another, particularly when the child has recently been ill or has developed new respiratory symptoms.

The dose should also be measured precisely. OIT is based on controlled exposure, not on estimating a portion of ordinary food by sight. Caregivers need to know how to prepare the treatment, when to administer it, what symptoms to observe, and which symptoms require immediate emergency action.

Defining success: thresholds and protection in pediatric patients

Desensitization means that a child can tolerate more allergen while continuing regular treatment than they could before therapy. It does not automatically mean that the immune system has permanently lost its allergic response.

This is the central distinction between desensitization and sustained unresponsiveness. Desensitization depends on ongoing exposure and may diminish if maintenance is interrupted. Sustained unresponsiveness refers to continued tolerance after a period without treatment, and the long-term rate of this outcome is not yet established across all pediatric age groups and allergens.

For families, the practical benefit may be substantial even when permanent tolerance has not been demonstrated. A child who previously reacted to a trace exposure may develop a higher reaction threshold, creating a greater margin of safety against accidental ingestion. That margin is clinically meaningful, but it does not remove the need for avoidance strategies, an emergency plan, or access to epinephrine.

Recent pediatric data illustrate why outcome definitions matter. In a 2024 Canadian study of infants and preschoolers, approximately 80% of children who reached maintenance dosing were successfully desensitized after about one year of therapy, with the ability to consume up to a serving size of the allergen food under the study’s assessment conditions. This is encouraging evidence for early intervention, but it should not be translated into a guarantee for every child entering treatment.

A separate study of preschool children undergoing peanut OIT reported that, among those who completed one year of maintenance, 78.6% had no symptoms during a cumulative challenge involving 4,000 mg of peanut protein. At the same time, 98.3% reacted at a cumulative dose of 1,000 mg or more in the evaluation described by the study. These findings require careful reading: the challenge dose, the protocol, and the patient population shape the result. A threshold observed in a supervised clinical setting is not identical to unrestricted eating at home.

A well-designed care plan makes these boundaries explicit. Families should know whether the treatment goal is protection from accidental exposure, the ability to eat a specified amount, improved participation in school and social events, or a combination of these outcomes.

The impact of early intervention

The immune system is not static during childhood, and this is one reason early oral immunotherapy has attracted significant clinical interest. Infants and preschoolers may have a different treatment profile from older children, although age alone does not determine suitability or outcome.

The 2024 Canadian findings are important because they focus on very young children and show that a substantial proportion of those reaching maintenance achieved desensitization after approximately one year. The data support a management conversation about timing: waiting may be appropriate for some children, but early referral can prevent families from postponing a specialist assessment simply because the child is young.

We should also separate the idea of early assessment from the idea of automatically starting OIT. A young child still requires a confirmed and clinically meaningful food allergy diagnosis, an individualized risk assessment, and a family that understands the daily responsibilities. Early treatment is not the same as rushed treatment.

The potential benefits of starting earlier include:

• a longer period in childhood during which the family may gain protection from accidental exposure;
• the possibility of increasing the reaction threshold before school, travel, camps, and social eating become more complex;
• an opportunity to address food-related anxiety while the child’s routines are still largely shaped by caregivers;
• earlier integration of allergy management with asthma, eczema, and other atopic conditions.

The potential burdens also deserve an unvarnished discussion. Daily dosing can be difficult when families travel, when the child refuses the food vehicle, or when illness disrupts the schedule. Some children experience symptoms during escalation or maintenance, and the family must remain prepared to treat a serious reaction. The management pathway is successful only when it fits the child’s health and the household’s practical capacity.

Managing the escalation phase: safety, side effects, and clinical reality

Adverse symptoms during OIT are common, particularly during dose escalation. In some trials, reactions occurred in up to 95% of patients. The reassuring part is that more than 85–95% of reported reactions were mild skin or gastrointestinal symptoms that resolved spontaneously or required only antihistamines. The important qualification is that mild reactions are not the same as no risk.

Symptoms may include oral itching, transient hives, abdominal discomfort, nausea, or vomiting. Respiratory symptoms, progressive throat symptoms, marked lethargy, repetitive vomiting, or signs of anaphylaxis require the emergency response outlined by the treating team. We should never assume that a reaction will remain mild because previous reactions were mild.

Epinephrine remains part of the safety plan during OIT. Starting therapy does not make accidental exposure harmless, and it does not justify discarding prescribed autoinjectors. Every caregiver who may give the daily dose or supervise the child should know where the emergency medication is kept and when it should be used.

The escalation phase is usually the point at which families learn whether the protocol is manageable in real life. A child may tolerate a dose on one day and develop symptoms on another because the immune response is influenced by more than the allergen amount alone. For that reason, dose changes should be directed by the clinical team rather than improvised at home.

A practical monitoring record can help the team distinguish a one-time event from a pattern. It may include:

• the date and time of the dose;
• the dose amount and food vehicle;
• recent illness, fever, or asthma symptoms;
• exercise or unusual physical activity near the dosing window;
• the onset, duration, and type of symptoms;
• medication given and the child’s response.

This is not a substitute for clinical advice, but it gives the allergist a clearer view of the child’s immune response and may support a safer adjustment to the schedule.

Asthma and the wider allergic profile

Food allergy OIT does not occur in isolation from the rest of pediatric immunology. Poorly controlled asthma can complicate the assessment and emergency management of allergic reactions, while eczema, allergic rhinitis, and other atopic disease may affect the child’s daily symptom burden.

The treatment plan should therefore include more than the target food. We need to ask whether asthma is controlled, whether inhaled medications are being used as prescribed, whether eczema is disrupting sleep, and whether the family recognizes the difference between a chronic baseline symptom and a new reaction after dosing.

This broader review is especially important when a child has frequent cough, wheeze, nighttime symptoms, or recent urgent care visits. The aim is not to exclude every child with another allergic condition, but to make sure the immune and respiratory background is stable enough for the selected pathway.

Beyond the protocol: quality of life and long-term considerations

The reason many families consider oral immunotherapy is not simply laboratory evidence of an altered immune response. It is the daily reality of food allergy: reading labels, questioning shared foods, communicating with school staff, managing birthday parties, and worrying about a child eating outside the home.

Quality-of-life outcomes are therefore central, not secondary. Findings presented at the ACAAI 2025 Scientific Meeting reported that 64% of children aged 0–12 who completed OIT were able to freely eat their target allergen, while nearly 90% of families reported improved quality-of-life scores and reduced mealtime anxiety. These findings suggest that successful OIT can change the emotional and practical landscape of allergy management, although the degree of benefit will vary by child, family, allergen, and treatment experience.

The phrase “freely eat” also needs clinical context. It should not be read as permission to stop following the maintenance schedule or to ignore the possibility of a reaction. In many treatment pathways, the child continues the maintenance dose even after a supervised challenge has demonstrated a higher threshold. The ongoing routine is part of preserving desensitization.

Long-term planning should address several questions:

• What is the maintenance dose, and how consistently must it be given?
• What should the family do after a missed dose?
• How should dosing be handled during fever, vomiting, asthma symptoms, or travel?
• When will the child be reassessed?
• Is a supervised challenge planned, and what will its result change?
• How will the plan evolve as the child enters school, adolescence, or a more independent stage of self-management?

There is no universal answer to how long maintenance should continue. Evidence remains incomplete regarding sustained unresponsiveness after stopping daily therapy across all ages and allergens. We should be precise about what the available research supports: OIT can raise the reaction threshold and may improve protection and quality of life, but it should not be presented as a guaranteed permanent cure.

The best treatment plan is the one that increases protection without making the child’s daily life unmanageable.

Building a durable management pathway

A successful pediatric OIT program depends on the relationship between the clinical team and the family. The protocol provides the structure, but the child’s symptoms, routines, development, and quality of life determine how that structure works in practice.

For some children, the key milestone is reaching the standard peanut maintenance dose. For others, it is remaining stable on a lower dose, reducing anxiety around school meals, or completing a supervised challenge without symptoms. We should measure progress against the treatment goal agreed at the beginning rather than against a single headline percentage.

The evidence for early intervention is increasingly supportive, particularly in infants and preschoolers who can complete the treatment pathway. The evidence also remains appropriately cautious: reactions are common, severe reactions remain possible, maintenance may need to continue, and protocols are not interchangeable across allergens.

When you are considering food allergy oral immunotherapy milestones for your child, the most useful next step is a specialist discussion that maps the full route: diagnosis, eligibility, escalation, up-dosing, maintenance, emergency readiness, and long-term follow-up. With that structure in place, OIT becomes neither an all-or-nothing promise nor an experiment conducted at home, but a monitored clinical strategy designed to increase safety and preserve quality of life.